Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability

Table 2 Infusion reactions per cohort, type and severity

	Standard cohort, n (%)	Rapid cohort, n (%)
	2214 infusions/169 patients	1461 infusions/129 patients
Mild reaction1
RR per infusion	0.8%	0.7%
RR per patient	10.7%	7.8%
Severe reaction1
RR per infusion	0.2%	0.00%
RR per patients	3.0%	0.00%
Total ADRs to infliximab	23 (%)	8 (%)
Mild ADRs1 (by subtype)	16 (69.6)	8 (100.0)
Serum sickness	1 (4.3)	1 (25.0)
Skin rash (including psoriasis/lupus)	6 (26.1)	4 (50.0)
Facial flushing	1 (4.3)	0 (0.0)
Hypoxia	0 (0.0)	2 (25.0)
Nausea	2 (8.7)	1 (12.5)
Pruritis	2 (8.7)	0 (0.0)
Arthralgia	1 (4.3)	0 (0.0)
Other (unspecified)	3 (13.0)	0 (0.0)
Severe ADRs1 (by subtype)	7 (30.4)	0 (0.0)
Anaphylactic (incl. angioedema)	4 (17.4)	0 (0.0)
Dyspnoea	1 (4.3)	0 (0.0)
Hypotension	1 (4.3)	0 (0.0)
Chest pain	1 (4.3)	0 (0.0)
Other (unspecified)	0 (0.0)	0 (0.0)
Retrial outcomes2
Returned to rapid	NA	7
Returned to accelerated	NA	1
Returned to standard	15	0
ADR(s) occurred on retrial	3	0

¹As per Common Toxicity Criteria definitions;

²Fastest protocol to which tolerated on ongoing basis (i.e., ≥ 3 infusions). RR: Relative risk; ADR: Adverse drug reaction; NA: Not available.